ESH AL 2018 | The challenges of choosing the right target antigen in AML compared to ALL
Treatment outcomes for acute myeloid leukemia (AML) patients treated with immunotherapy have significantly lagged behind those achieved for acute lymphoblastic leukemia (ALL), and this is due to the fact that eliminating the B-cell lineage for the management of ALL is less problematic than eliminating the myeloid lineages involved in AML. In this interview, Marion Subklewe, MD, from the Ludwig-Maximilians University Hospital of Munich, Munich, Germany, explores the antigens targeted for the treatment of ALL, such as CD22, CD20 and CD19. Dr Subklewe also discusses the other factors that play a role in choosing the right AML targets, including cofactors and antigen-antibody affinities. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
